Atrium Therapeutics, Inc. Statistics
Want to see RNA full AI Analyst Report?
Atrium Therapeutics, Inc. (RNA) Stock Statistics & Valuation Metrics
Total Valuation
Atrium Therapeutics, Inc. has a market cap or net worth of $162.00M. The enterprise value is -$32.45M.
- Market Cap
- $162.00M
- Enterprise Value
- -$32.45M
Share Statistics
Atrium Therapeutics, Inc. has 21,571,507 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 21,571,507
- Owned by Insiders
- 2.21%
- Owned by Institutions
- 31.56%
Financial Efficiency
Atrium Therapeutics, Inc.’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -31.92%.
- Return on Equity (ROE)
- -0.37
- Return on Assets (ROA)
- -0.28
- Return on Invested Capital (ROIC)
- -31.92%
- Return on Capital Employed (ROCE)
- -0.32
- Revenue Per Employee
- 36.43K
- Profits Per Employee
- -150.07K
- Employee Count
- 511
- Asset Turnover
- 0.07
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Atrium Therapeutics, Inc. is -1.83. Atrium Therapeutics, Inc.’s PEG ratio is 0.02.
- PE Ratio
- -1.83
- PS Ratio
- 4.17
- PB Ratio
- 0.62
- Price to FCF
- -1.95
- Price to Operating Cash Flow
- -1.61
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Atrium Therapeutics, Inc. had revenue of 18.62M and earned -76.68M in profits. Earnings per share was -4.48.
- Revenue
- 18.62M
- Gross Profit
- 18.62M
- Operating Income
- -76.81M
- Pretax Income
- -76.83M
- Net Income
- -76.68M
- EBITDA
- -76.50M
- Earnings Per Share (EPS)
- -4.48
Cash Flow
In the last 12 months, operating cash flow was -79.69M and capital expenditures -3.43M, giving a free cash flow of -83.12M billion.
- Operating Cash Flow
- -79.69M
- Free Cash Flow
- -83.12M
- Free Cash Flow per Share
- -4.88
Dividends & Yields
Atrium Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -51.31%
- Earnings Yield
- -69.68%
Stock Price Statistics
- Beta
- 1.06
- 52-Week Price Change
- -49.08%
- 50-Day Moving Average
- 8.78
- 200-Day Moving Average
- 11.92
- Relative Strength Index (RSI)
- 32.73
- Average Volume (3m)
- 291.45K
Important Dates
Atrium Therapeutics, Inc. upcoming earnings date is ―, After Close (Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Atrium Therapeutics, Inc. as a current ratio of 6.53, with Debt / Equity ratio of 1.77%
- Current Ratio
- 6.53
- Quick Ratio
- 6.53
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 3.48
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Atrium Therapeutics, Inc. has paid -142.00K in taxes.
- Income Tax
- -142.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Atrium Therapeutics, Inc. EV to EBITDA ratio is -1.30, with an EV/FCF ratio of -1.42.
- EV to Sales
- 3.04
- EV to EBITDA
- -1.30
- EV to Free Cash Flow
- -1.42
- EV to Operating Cash Flow
- -1.48
Balance Sheet
Atrium Therapeutics, Inc. has $232.07M in cash and marketable securities with $679.00K in debt, giving a net cash position of $231.40M billion.
- Cash & Marketable Securities
- $232.07M
- Total Debt
- $679.00K
- Net Cash
- $231.40M
- Net Cash Per Share
- $10.73
- Tangible Book Value Per Share
- $12.03
Margins
Gross margin is 42.18%, with operating margin of -243.60%, and net profit margin of -229.67%.
- Gross Margin
- 42.18%
- Operating Margin
- -243.60%
- Pretax Margin
- -229.58%
- Net Profit Margin
- -229.67%
- EBITDA Margin
- -233.35%
- EBIT Margin
- -235.84%
Analyst Forecast
The average price target for Atrium Therapeutics, Inc. is $21.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $21.25
- Price Target Upside
- 182.96% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 8
- AI Score
- 44

